Axxam, a leading drug discovery company with expertise in early phase discovery biology, and Mercachem, a leading discovery chemistry company with expertise in both medicinal and process chemistry, announce a strategic alliance to provide integrated discovery services spanning all phases from gene to fully optimized Leads and beyond.
This partnership will allow the companies to offer best-in-class fully integrated drug discovery services, supported by a culture of scientific excellence and innovation.
Stefan Lohmer, co-founder and Chief Executive Officer of Axxam, says, “The complementary and comprehensive skillsets of Axxam and Mercachem provide a concrete solution to the increasing demands of the market for integrated drug discovery services of the highest quality”.
Frank Leemhuis, Managing Director of Mercachem adds “Understanding the underlying mechanisms of enzyme inhibition and ligand–receptor interactions allows biological challenges to be solved through high-quality chemistry. We believe that Axxam and Mercachem with their respective platforms, know-how and track record in the service business are ideally suited to fully exploit this unique combination of core competencies”.
Read the full press release here.